Prostate,

Question 1

Stampede trial 2016 result
(Arm C)

Answer 1

Stampede is a trial of high risk, locally advanced or metastatic prostate cancer who are starting first line long term hormone therapy.

Stratified to
- adt + optional RT (SOC)
- soc + zolendronic acid
- soc + docetaxel chemo
- soc + doc + za

Median OS 71 months in SOC, 81mo in docetaxel arm

Early docetaxel improves median survival

Question 2

Stampede trial 2017 update

Answer 2

Men randomised to adt alone or ADT plus abiraterone plus prednisolone.

Hazard ratio for death was 0.63 favouring combined group.

HR 0.75 in non metastatic, 0.61 in metastatic